Assenagon Asset Management S.A. Has $1.22 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Assenagon Asset Management S.A. trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 82.3% during the first quarter, HoldingsChannel reports. The fund owned 15,897 shares of the specialty pharmaceutical company’s stock after selling 73,880 shares during the quarter. Assenagon Asset Management S.A.’s holdings in ANI Pharmaceuticals were worth $1,222,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Divisadero Street Capital Management LP acquired a new position in shares of ANI Pharmaceuticals during the third quarter worth $21,454,000. Apis Capital Advisors LLC grew its stake in shares of ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after purchasing an additional 36,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. Oliver Luxxe Assets LLC acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $1,823,000. Finally, Penn Capital Management Company LLC raised its position in ANI Pharmaceuticals by 2,058.9% during the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after purchasing an additional 131,030 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Thomas Haughey sold 2,000 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $82.03, for a total value of $41,015.00. Following the sale, the vice president owned 77,890 shares in the company, valued at approximately $6,389,316.70. The trade was a 0.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 81,866 shares of company stock worth $6,435,733. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Trading Up 0.3%

NASDAQ:ANIP opened at $83.05 on Thursday. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm’s fifty day moving average is $80.77 and its 200-day moving average is $79.35. The firm has a market cap of $1.89 billion, a P/E ratio of 21.03 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent research reports. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.